Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

p>(2) Other items -- Non-GAAP net loss and diluted net loss per common share

exclude other unusual or non-recurring items that are evaluated on an

individual basis. Amicus' evaluation of whether to exclude an item for

purposes of determining its non-GAAP financial measures considers both

the quantitative and qualitative aspects of the item, including, among

other things (i) its size and nature, (ii) whether or not it relates

to its ongoing business operations, and (iii) whether or not Amicus

expects it to occur as part of its normal business on a regular basis.

Items excluded for purposes of determining non-GAAP net loss and

diluted net loss per common share include deemed dividends, preferred

stock accretion, and changes in the fair value of warrant liability.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and webcast today, Monday, November 3, 2008, at 5:00 P.M. EST to review financial results and recent developments. Interested participants and investors may access the conference call at 5 P.M. EST by dialing 877-419-6591 (U.S./Canada) or 719-325-4858 (international).

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 90 days.

A telephonic replay of the call will be available for seven days beginning at 8 p.m. EST. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4499321.

Amic
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is ... of BNC105 in patients with metastatic renal cancer at ... Florida . The data will be presented by ... Hope Comprehensive Cancer Center in California ... new data identifies Ferritin and IL-8 as two baseline ...
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... 2015   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today reported 2014 ... other key objectives, and financial guidance.  Synageva,s management ... 4:30 p.m. EST to review the financial results ... in today,s call by telephone, please dial (877) ...
(Date:2/26/2015)... On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript’s ... for judgment notwithstanding the verdict, a new trial, and ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Mich., Oct. 11 Compendia Bioscience, Inc.,today announced ... Track Award from,the National Cancer Institute to support ... Platform for Biopharmaceutical Research and,Development". (Logo: ... Ph.D., who will serve as the principal,investigator for ...
... the prevention and treatment of ... safety and comfort, BATESVILLE, Ind., Oct. 11 ... Hill-Rom subsidiary has,introduced a revolutionary new hospital bed surface ... Hill-Rom(R) E700 Wound Surface (a,low air loss therapy surface) ...
... provides pharmacy staff with the ability to ... manage every pharmaceutical in the hospital, MOUNTAIN VIEW, Calif. ... ), a leading provider,of system solutions to acute healthcare facilities, ... Chambersburg,Hospital has reduced cart-fill time from 16 man-hours to 90 ...
Cached Biology Technology:Compendia Bioscience Announces the Receipt of a $2.4M SBIR Award and Related Management Changes 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 2Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 3Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 4Hill-Rom Introduces New Wound Therapy Surface With Innovative Safety and Treatment Features 5Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0 2Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0 3
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
(Date:2/5/2015)... North Carolina , 5. Februar 2015 ... Jahr als spezialisiertes Logistikunternehmen und hat eine ... einzige klinische Logistikfirma (Clinical Logistics Organization – ... der neuen Kampagne lautet First , ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... Princeton engineers have developed a sensor that may revolutionize how ... the process also help ensure the survival of two species ... credit goes to an African frog. In the wild, ... of amino acids -- on its skin to protect it ...
... of Medicine have found that new disease pathways involving ... Gaucher disease, a rare genetic disorder in which fatty ... enlargement, osteoporosis, bone pain, and increased risk of cancer ... lead to less expensive and more effective ways to ...
... COLUMBIA, Mo. If finding the cure for a fungus ... of a detective show, University of Missouri Chemistry Professor John ... high-tech equipment to make a model that could eventually solve ... of Arts and Science, has joined forces with Pablo Sobrado, ...
Cached Biology News:New sensor derived from frogs may help fight bacteria and save wildlife 2New sensor derived from frogs may help fight bacteria and save wildlife 3Cheaper, more effective treatment of type 1 Gaucher disease possible 2X-ray diffraction may play key role in stopping 'kissing bug,' fungus 2
A univariate (peak height or area) quantitative multi-component analysis package....
... H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH 2 (Disulfide ... peptide and 1 ... I-labelled peptide, please see ... ([ 1 2 ...
... is a dramatic breakthrough in accurate, small-volume bulk ... resolution, the micro 1 has unique advantages not ... micro 1 never needs re-calibration as do other ... on an LCD Display , Graphical Row Selection ...
... high-throuput screening of a biological systems phenotype, ... changes in the expression levels of the ... studied, classified and compared to each other, ... a glance. Automatized scanning of the hybridized ...
Biology Products: